The value of vesicant 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in gastric malignancies

Nucl Med Commun. 2004 Aug;25(8):825-31. doi: 10.1097/01.mnm.0000135042.54461.f6.

Abstract

Aim: The value of vesicant 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in the detection and staging of primary gastric malignancies was studied prospectively.

Methods: Thirty-eight patients with suspected gastric tumour were imaged with three-dimensional PET after the injection of 18F-FDG. During the PET study, vesicant was given orally in order to extend the stomach with CO(2) gas. Surgical operation (n=31) or gastric endoscopy with biopsy (n=7) was undertaken 3-26 days after the PET study. The PET results were compared with clinical (computed tomography/magnetic resonance imaging/ultrasound), surgical and histological staging.

Results: PET correctly diagnosed 83.3% of primary malignant (25/30) and benign (7/8) lesions, and corrected 11 clinically and five surgically mis-staged cases. Five primaries were false-negatives in quantitative analysis, but qualitative PET readings revealed positive lymph nodes, thereby providing a correct diagnosis in two of the five. PET misdiagnosed seven N1, one N2 and one false-positive case. The focal uptake of 18F-FDG was correlated with the differentiation, size and depth of invasion of the gastric tumours.

Conclusions: 18F-FDG PET is useful for the detection and staging of primary gastric malignancies, and the administration of vesicant may improve the diagnostic confidence.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / diagnostic imaging*
  • Adenocarcinoma / pathology
  • Adult
  • Aged
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Irritants*
  • Male
  • Middle Aged
  • Positron-Emission Tomography / methods*
  • Radiopharmaceuticals
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Stomach Neoplasms / diagnostic imaging*
  • Stomach Neoplasms / pathology

Substances

  • Irritants
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18